9月15日至17日，德國著名骨腫瘤專家Lehner教授訪問南方醫(yī)科大學第三附屬醫(yī)院。Lehner教授現(xiàn)任海德堡大學附屬醫(yī)院骨科與創(chuàng)傷外科骨腫瘤分科及感染性骨外科主任、海德堡認證肉瘤中心主任，在骨與軟組織腫瘤領(lǐng)域享有盛譽。該院副院長王亮、骨腫瘤科李浩淼主任及團隊共同為Lehner教授舉行別開生面的歡迎儀式。在為期三天的工作中，Lehner教授與骨腫瘤團隊開展了深入交流，通過門診、查房、病例討論、手術(shù)指導以及大師公開課等多種形式分享了中德雙方在骨與軟組織腫瘤手術(shù)治療、腫瘤假體周圍感染等方面的臨床經(jīng)驗與技術(shù)進展。Lehner教授充分肯定該院人才儲備和專業(yè)水平。李浩淼主任曾去傳說中的意大利里佐利骨科研究所學習了一年。師從世界脊柱腫瘤大師Boriani 教授。2012年建科，13載精耕細作，每年1500臺標志性手術(shù)。為每位病人提供定制化的專業(yè)服務(wù)。Lehner教授分享了未來骨腫瘤的科研與臨床進展將更多聚焦于腫瘤內(nèi)科方向。如放療、化療以及新型藥物療法，這將具有廣闊的發(fā)展?jié)摿?。成立骨腫瘤內(nèi)科團隊更有助于持續(xù)跟進非手術(shù)治療的前沿動態(tài)與治療策略，為患者提供更全面的治療方案。本次中德合作是南方醫(yī)科大學第三附屬醫(yī)院骨腫瘤團隊與海德堡大學附屬醫(yī)院一次高水平國際對話。中國醫(yī)療要發(fā)展，還是需要很多有雄心、有全球思考、有抱負、正直的醫(yī)生，他們才是未來中國醫(yī)療的希望。

From September 15 to 17, Prof. Lehner, a renowned German expert in orthopedic oncology, visited the Southern Medical University Third Hospital. Prof. Lehner is the Director of the Section of Orthopedic Oncology and Septic Orthopedic Surgery of Clinic for Orthopedics at Heidelberg University Hospital, as well as the Head of Certified Sarcoma Center Heidelberg, with high influence and reputation in the field of bone and soft tissue tumors. A distinctive welcome ceremony was held for Prof. Lehner by Prof. WANG Liang, Vice Hospital President, Prof. LI Haomiao, the Director of the Department of Orthopedic Oncology and his team. During the three-day visit, Prof. Lehner engaged in in-depth exchanges with the host team. Both sides shared clinic experiences and technological advances in surgical treatment of bone and soft tissue tumors, as well as in managing tumor prosthesis-related periprosthetic infection through various activities such as joint outpatient consultation, joint ward rounds, cases discussions, operation observation and public lectures. Prof. Lehner spoke highly of the talent pool and the expertise of the host team. Prof. LI Haomiao had previously stayed at the Rizzoli Orthopaedic Institute in Italy for one year under the guidance of Prof. Boriani, a world-class master in spine tumor. Since its establishment in 2012, the department had been dedicated to excellence for 13 years, performs 1500 signature surgeries annually and provides customized professional care for each patient. Prof. Lehner noted that future research and clinical advences in bone tumors are expected to shift more toward medical oncology, including radiotherapy, chemotherapy and novel drug therapies, which hold broad potential for development. Establishing a dedicated bone tumor medical oncology team will facilitate continuous tracking of the latest developments and treatment strategies of non-surgery therapies, thereby providing patients with more comprehensive treatment options. The visit is a high-level international exchange between the orthopedic oncology team at Southern Medical University Third Hospital and Heidelberg University Hospital. The advancement of healthcare in China depends on doctors who have great ambition, global thinking, aspiration and integrit. They are the true future of Chinese healthcare.